CN109475629A - 用notch和pd-1或pd-l1抑制剂的组合治疗 - Google Patents

用notch和pd-1或pd-l1抑制剂的组合治疗 Download PDF

Info

Publication number
CN109475629A
CN109475629A CN201780044786.9A CN201780044786A CN109475629A CN 109475629 A CN109475629 A CN 109475629A CN 201780044786 A CN201780044786 A CN 201780044786A CN 109475629 A CN109475629 A CN 109475629A
Authority
CN
China
Prior art keywords
cancer
monoclonal antibody
carcinoma
oxo
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780044786.9A
Other languages
English (en)
Chinese (zh)
Inventor
M.H.本德
高红
B.K.帕特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to CN202211692364.1A priority Critical patent/CN115845070A/zh
Publication of CN109475629A publication Critical patent/CN109475629A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780044786.9A 2016-05-20 2017-05-16 用notch和pd-1或pd-l1抑制剂的组合治疗 Pending CN109475629A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211692364.1A CN115845070A (zh) 2016-05-20 2017-05-16 用notch和pd-1或pd-l1抑制剂的组合治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662339363P 2016-05-20 2016-05-20
US62/339363 2016-05-20
PCT/US2017/032790 WO2017200969A1 (en) 2016-05-20 2017-05-16 Combination therapy with notch and pd-1 or pd-l1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211692364.1A Division CN115845070A (zh) 2016-05-20 2017-05-16 用notch和pd-1或pd-l1抑制剂的组合治疗

Publications (1)

Publication Number Publication Date
CN109475629A true CN109475629A (zh) 2019-03-15

Family

ID=58772978

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211692364.1A Pending CN115845070A (zh) 2016-05-20 2017-05-16 用notch和pd-1或pd-l1抑制剂的组合治疗
CN201780044786.9A Pending CN109475629A (zh) 2016-05-20 2017-05-16 用notch和pd-1或pd-l1抑制剂的组合治疗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202211692364.1A Pending CN115845070A (zh) 2016-05-20 2017-05-16 用notch和pd-1或pd-l1抑制剂的组合治疗

Country Status (15)

Country Link
US (2) US10688104B2 (enExample)
EP (1) EP3458091B1 (enExample)
JP (1) JP7194022B2 (enExample)
KR (1) KR102463617B1 (enExample)
CN (2) CN115845070A (enExample)
AU (1) AU2017268187A1 (enExample)
BR (1) BR112018073673A2 (enExample)
CA (1) CA3025024A1 (enExample)
ES (1) ES2904880T3 (enExample)
IL (1) IL263110B (enExample)
MA (1) MA45025A (enExample)
MX (1) MX2018013941A (enExample)
SG (1) SG11201810268YA (enExample)
WO (1) WO2017200969A1 (enExample)
ZA (1) ZA201807585B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
BR112018000768A2 (pt) 2015-07-13 2018-09-25 Cytomx Therapeutics Inc anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
WO2017180385A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
ES2881801T3 (es) 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
CA3025024A1 (en) 2016-05-20 2017-11-23 Eli Lilly And Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
EP3823669A1 (en) * 2017-12-18 2021-05-26 Debiopharm International SA Combination of an agonist anti-pd-1 antibody with a gnrh agonist or antagonist to treat cancer
US20220370397A1 (en) * 2019-10-28 2022-11-24 Enzychem Lifesciences Corporation Methods and compositions for treatment of cancer
KR20240004519A (ko) * 2021-04-28 2024-01-11 아센타위츠 파마슈티컬즈 리미티드 면역관문 억제제와 함께 akr1c3-활성화 화합물을 사용하는 병용 요법
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073732A1 (en) * 2003-02-18 2004-09-02 Lorantis Limited Modulators of notch signalling and of immune cell costimulatory activity for immunotherapy
CN101248089A (zh) * 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
JP2013532153A (ja) * 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
CN103732612A (zh) * 2011-07-27 2014-04-16 伊莱利利公司 Notch通路信号转导抑制剂化合物
JP2014525918A (ja) * 2011-08-01 2014-10-02 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
WO2015117164A1 (en) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders
WO2015193352A1 (en) * 2014-06-17 2015-12-23 Medimmune Limited Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy
WO2016040880A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
CN105451770A (zh) * 2013-08-20 2016-03-30 默沙东公司 使用PD-1拮抗剂和dinaciclib的组合治疗癌症
WO2016070051A2 (en) * 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2016069647A1 (en) * 2014-10-27 2016-05-06 Fred Hutchinson Cancer Research Center Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3812952B2 (ja) 1996-12-23 2006-08-23 エラン ファーマシューティカルズ，インコーポレイテッド シクロアルキル、ラクタム、ラクトンおよびその関連化合物およびその医薬組成物、並びに該化合物を用いたβ−アミロイドペプチドの放出および／またはその合成を阻害する方法
AU768269B2 (en) 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US7706658B2 (en) 2005-07-05 2010-04-27 Fujifilm Corporation Copolymer and polymerizable composition
DE102006002966A1 (de) * 2006-01-21 2007-07-26 Schaeffler Kg Laufscheibe mit integrierter Wälzkörperlaufbahn
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
EA017865B1 (ru) 2007-03-28 2013-03-29 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US8188069B2 (en) 2007-08-14 2012-05-29 Eli Lilly And Company Azepine derivatives as gamma-secretase inhibitors
BRPI0906831A2 (pt) 2008-01-11 2019-09-24 Hoffmann La Roche uso de um inibidor de gama-secretase para tratamento de câncer
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2470054B1 (de) 2009-08-26 2013-12-04 FrXsh AG Vorrichtung und verfahren zum mischen von mischgut
WO2011060051A1 (en) 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
CN102085372A (zh) 2009-12-04 2011-06-08 中国医学科学院基础医学研究所 Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9698876B2 (en) 2013-07-23 2017-07-04 Telefonaktiebolaget Lm Ericsson (Publ) Transmission mode allocation in LTE networks
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
US9465158B2 (en) * 2014-09-04 2016-10-11 National Taiwan Normal University Light-guide coupler for modulating angular and spatial distributions of light source
HUE053995T2 (hu) 2014-12-05 2021-08-30 Memorial Sloan Kettering Cancer Center B-sejt-érési antigént célzó antitestek és alkalmazási eljárások
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
CN108025001A (zh) 2015-07-24 2018-05-11 安可初克公司 用于治疗免疫系统功能障碍的γ分泌酶调节剂
ES2881801T3 (es) 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
WO2017180385A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
CA3025024A1 (en) 2016-05-20 2017-11-23 Eli Lilly And Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
KR102512899B1 (ko) 2016-08-31 2023-03-23 일라이 릴리 앤드 캄파니 고형 종양의 치료를 위한 투약 요법
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073732A1 (en) * 2003-02-18 2004-09-02 Lorantis Limited Modulators of notch signalling and of immune cell costimulatory activity for immunotherapy
CN101248089A (zh) * 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
JP2013532153A (ja) * 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
CN103732612A (zh) * 2011-07-27 2014-04-16 伊莱利利公司 Notch通路信号转导抑制剂化合物
JP2014525918A (ja) * 2011-08-01 2014-10-02 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
CN105451770A (zh) * 2013-08-20 2016-03-30 默沙东公司 使用PD-1拮抗剂和dinaciclib的组合治疗癌症
WO2015117164A1 (en) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders
WO2015193352A1 (en) * 2014-06-17 2015-12-23 Medimmune Limited Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy
WO2016040880A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
WO2016069647A1 (en) * 2014-10-27 2016-05-06 Fred Hutchinson Cancer Research Center Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
WO2016070051A2 (en) * 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DREW M PARDOLL: "The blockade of immune checkpoints in cancer immunotherapy", 《NAT REV CANCER》 *
EVAN J LIPSON ET AL.: "Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody", 《CLIN CANCER RES》 *
JAMES F. SHANAHAN AND CHRISTIE NAGLIERI 主编: "《Manual of Pharmacology and Therapeutics》", 31 December 2008, THE MCGRAW-HILL COMPANIES *
JOAN MAUREL & ANTONIO POSTIGO: "Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice", 《CURR CANCER DRUG TARGETS》 *
MÉLISSA MATHIEU ET AL.: "Notch signaling regulates PD-1 expression during CD8(+) T-cell activation", 《IMMUNOL CELL BIOL》 *
周彬 等: "Notch-1阻断剂对骨肉瘤小鼠模型肿瘤生长的抑制作用及相关分子机制探究", 《海南医学院学报》 *
郑杰编著: "《肿瘤的细胞和分子生物学》", 30 January 2011, 上海科学技术出版社 *

Also Published As

Publication number Publication date
MA45025A (fr) 2019-03-27
IL263110B (en) 2022-07-01
ES2904880T3 (es) 2022-04-06
US11826317B2 (en) 2023-11-28
BR112018073673A2 (pt) 2019-02-26
KR102463617B1 (ko) 2022-11-03
US20190192531A1 (en) 2019-06-27
SG11201810268YA (en) 2018-12-28
CN115845070A (zh) 2023-03-28
US20220008432A1 (en) 2022-01-13
KR20190008913A (ko) 2019-01-25
WO2017200969A1 (en) 2017-11-23
AU2017268187A1 (en) 2018-11-29
US10688104B2 (en) 2020-06-23
EP3458091A1 (en) 2019-03-27
JP7194022B2 (ja) 2022-12-21
CA3025024A1 (en) 2017-11-23
JP2019516733A (ja) 2019-06-20
IL263110A (en) 2018-12-31
EP3458091B1 (en) 2021-11-17
MX2018013941A (es) 2019-03-21
ZA201807585B (en) 2024-09-25

Similar Documents

Publication Publication Date Title
CN109475629A (zh) 用notch和pd-1或pd-l1抑制剂的组合治疗
Taylor et al. Glioblastoma multiforme: an overview of emerging therapeutic targets
Crinò et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
Moreno et al. Liposomal cytarabine for the treatment of leptomeningeal dissemination of central nervous system tumours in children and adolescents
CN109310684A (zh) 用于治疗癌症的notch和cdk4/6抑制剂的组合疗法
JP2019011376A (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
Krueger et al. Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
CN109310685A (zh) 用于治疗癌症的notch和pi3k/mtor抑制剂的组合疗法
Brown et al. Bortezomib, vorinostat, and dexamethasone combination therapy in relapsed myeloma: results of the phase 2 MUK four trial
KR20170134462A (ko) Mdm2 저해제와 btk 저해제의 병용 치료법
JP7747307B2 (ja) 抗癌剤耐性の軽減、及び抗癌剤の感受性の増強のための医薬組成物及びその使用
CN106265660A (zh) A674563在携带flt3突变型基因的急性白血病中的新用途
WO2016065674A1 (zh) 依鲁替尼对flt3-itd突变的急性白血病的应用
TW201834650A (zh) 哺乳類雷帕黴素靶蛋白抑制劑及氯喹於治療癌症之用途
TW202241455A (zh) 使用akr1c3活化化合物與免疫檢查點抑制劑之組合療法
TW202421147A (zh) 用於治療套細胞淋巴瘤(MCL)之阿貝西尼(Abemaciclib)及維奈托克(Venetoclax)的組合
Mehta et al. Ps1073 preliminary results of astx660, a novel non-peptidomimetic ciap1/2 and xiap antagonist, in relapsed/refractory peripheral T-cell lymphoma and cutaneous T cell lymphoma
WO2022105763A1 (zh) 靶向cd24的胃癌治疗方法
Xiao et al. DDDR-35. TARGETING GBM INVASION BY INHIBITING KCNA1 WITH 4-AMINOPYRIDINE: AN FDA APPROVED DRUG THAT EASILY PASS THROUGH THE BBB
Abueg et al. Biotherapies: Targeted Therapies and Immunotherapies
HK40004756B (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
HK40004756A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
Huy et al. Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer. Open Access Maced J Med Sci. 2019 Dec 30; 7 (24): 4244-4249

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination